Amphastar Pharmaceuticals reported second quarter 2026 financial results with net revenues of $183.9 million, a 5% increase from the prior year period. GAAP net income was $30.3 million, or $0.67 per diluted share, while adjusted non-GAAP net income reached $40.8 million, or $0.91 per diluted share. The company achieved its first annual net sales milestone for BAQSIMI under an agreement with Eli Lilly, triggering a $100 million payment due in the third quarter of 2026. Amphastar is a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products.

Amphastar Pharmaceuticals, Inc. announced that its subsidiary, International Medication Systems, Limited, received an FDA Warning Letter regarding current Good Manufacturing Practice violations at its South El Monte, California facility. The FDA cited issues with investigation procedures, environmental monitoring, and manufacturing equipment following a December 2025 inspection. The company is implementing a remediation plan and evaluating the impact on operations, though it cannot guarantee FDA satisfaction with the response. Amphastar Pharmaceuticals, Inc. is a pharmaceutical company that develops and manufactures generic and specialty injectable drugs.